Pharmacokinetics of Baricitinib in Cerebrospinal Fluid and Plasma in a Patient with SPENCD
Overview
Overview
Journal
J Clin Immunol
Publisher
Springer
Specialty
Allergy & Immunology
Date
2024 Mar 8
PMID
38457012
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Fremond M, Hully M, Fournier B, Barrois R, Levy R, Aubart M
. JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study. J Clin Immunol. 2023; 43(6):1436-1447.
PMC: 10175907.
DOI: 10.1007/s10875-023-01500-z.
View
2.
Cetin Gedik K, Lamot L, Romano M, Demirkaya E, Piskin D, Torreggiani S
. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. Ann Rheum Dis. 2022; 81(5):601-613.
PMC: 9036471.
DOI: 10.1136/annrheumdis-2021-221814.
View
3.
Briggs T, Rice G, Adib N, Ades L, Barete S, Baskar K
. Spondyloenchondrodysplasia Due to Mutations in ACP5: A Comprehensive Survey. J Clin Immunol. 2016; 36(3):220-34.
PMC: 4792361.
DOI: 10.1007/s10875-016-0252-y.
View
4.
Vanderver A, Adang L, Gavazzi F, McDonald K, Helman G, Frank D
. Janus Kinase Inhibition in the Aicardi-Goutières Syndrome. N Engl J Med. 2020; 383(10):986-989.
PMC: 7495410.
DOI: 10.1056/NEJMc2001362.
View
5.
Kim H, Brooks K, Tang C, Wakim P, Blake M, Brooks S
. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients. Clin Pharmacol Ther. 2017; 104(2):364-373.
PMC: 6089664.
DOI: 10.1002/cpt.936.
View